Add to Favorites Newsroom RSS Share
Philadelphia, PA USA

Our News on Newswise

Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons

Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.
6-Sep-2018 1:15 PM EDT Add to Favorites

Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination

A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published...
5-Sep-2018 11:40 AM EDT Add to Favorites

Synthetic DNA Technology Provides a Novel Strategy for Effective Delivery of a Complex Anti-HIV Agent

Wistar scientists have applied their synthetic DNA technology to engineer a novel eCD4-Ig anti-HIV agent and to enhance its potency in vivo, providing a new simple strategy for constructing complex therapeutics for infectious agents as well as for...
4-Sep-2018 1:05 PM EDT Add to Favorites

Wistar Receives Support of More Than $5.5M from Private Foundations and Funding Agencies

Wistar received more than $5.5 million in grants and awards from local foundations, and national and international funding agencies to support research, education and training at the Institute.
7-Aug-2018 2:45 PM EDT Add to Favorites

Older Melanoma Patients Have Better Response to Immune Checkpoint Blockade Therapy

Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.
12-Jun-2018 3:30 PM EDT Add to Favorites

The Wistar Institute and Harbour BioMed Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases

Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
4-Jun-2018 12:05 PM EDT Add to Favorites

Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization

Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of...
27-Apr-2018 12:05 PM EDT Add to Favorites

Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in...
25-Apr-2018 12:05 PM EDT Add to Favorites


see all news

Our YouTube Videos

About

As a nonprofit biomedical research institution, The Wistar Institute is committed to conducting basic research to benefit society and to training the next generation of scientists. Integrity in research is essential to expanding our knowledge of the basic biological processes fundamental to life. All faculty, staff, trainees, and students involved in research at The Wistar Institute are required to maintain the highest standards of ethical conduct in research and to adhere to the rules and regulations of federal agencies governing biomedical research. Faculty and senior research staff are expected to serve as mentors to trainees and students, teaching them the standards of ethical practice in research. Elements of integrity in research include intellectual honesty in conducting and reporting research, maintenance of accurate research records and results, proper allocation of credit among co-authors of studies, fairness in peer review, openness in communications and sharing of resources, transparency in potential conflicts of interest, humane care of animals in the conduct of research, and protection of human subjects in the conduct of research.

Contacts

Darien Sutton
Media Relations & Communications Manager

215-898-3988

Tara Yates
Director of Communications
cancer

215-898-3826

Twitter

Chat now!